S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.05 (-1.72%)
AAPL   164.70 (-0.36%)
MSFT   330.14 (-0.14%)
FB   310.46 (-4.31%)
GOOGL   2,820.00 (-0.63%)
AMZN   3,441.71 (-1.86%)
TSLA   1,090.89 (-4.71%)
NVDA   314.25 (-3.83%)
BABA   122.35 (-4.06%)
NIO   38.40 (-1.87%)
CGC   9.94 (-7.19%)
AMD   149.23 (-5.77%)
GE   92.97 (-2.13%)
MU   84.79 (+0.94%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.02 (-1.99%)
PFE   54.80 (+1.99%)
AMC   30.13 (-11.23%)
ACB   6.01 (-6.39%)
BA   187.80 (-5.08%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.05 (-1.72%)
AAPL   164.70 (-0.36%)
MSFT   330.14 (-0.14%)
FB   310.46 (-4.31%)
GOOGL   2,820.00 (-0.63%)
AMZN   3,441.71 (-1.86%)
TSLA   1,090.89 (-4.71%)
NVDA   314.25 (-3.83%)
BABA   122.35 (-4.06%)
NIO   38.40 (-1.87%)
CGC   9.94 (-7.19%)
AMD   149.23 (-5.77%)
GE   92.97 (-2.13%)
MU   84.79 (+0.94%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.02 (-1.99%)
PFE   54.80 (+1.99%)
AMC   30.13 (-11.23%)
ACB   6.01 (-6.39%)
BA   187.80 (-5.08%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.05 (-1.72%)
AAPL   164.70 (-0.36%)
MSFT   330.14 (-0.14%)
FB   310.46 (-4.31%)
GOOGL   2,820.00 (-0.63%)
AMZN   3,441.71 (-1.86%)
TSLA   1,090.89 (-4.71%)
NVDA   314.25 (-3.83%)
BABA   122.35 (-4.06%)
NIO   38.40 (-1.87%)
CGC   9.94 (-7.19%)
AMD   149.23 (-5.77%)
GE   92.97 (-2.13%)
MU   84.79 (+0.94%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.02 (-1.99%)
PFE   54.80 (+1.99%)
AMC   30.13 (-11.23%)
ACB   6.01 (-6.39%)
BA   187.80 (-5.08%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.05 (-1.72%)
AAPL   164.70 (-0.36%)
MSFT   330.14 (-0.14%)
FB   310.46 (-4.31%)
GOOGL   2,820.00 (-0.63%)
AMZN   3,441.71 (-1.86%)
TSLA   1,090.89 (-4.71%)
NVDA   314.25 (-3.83%)
BABA   122.35 (-4.06%)
NIO   38.40 (-1.87%)
CGC   9.94 (-7.19%)
AMD   149.23 (-5.77%)
GE   92.97 (-2.13%)
MU   84.79 (+0.94%)
T   22.22 (-2.67%)
F   19.63 (+2.29%)
DIS   142.02 (-1.99%)
PFE   54.80 (+1.99%)
AMC   30.13 (-11.23%)
ACB   6.01 (-6.39%)
BA   187.80 (-5.08%)
NASDAQ:ALPN

Alpine Immune Sciences Insider Trades

$10.94
+0.11 (+1.02%)
(As of 12/1/2021 03:59 PM ET)
Add
Compare
Today's Range
$10.81
$11.51
50-Day Range
$10.36
$13.75
52-Week Range
$7.87
$16.37
Volume
3,784 shs
Average Volume
109,559 shs
Market Capitalization
$319.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.55

Alpine Immune Sciences (NASDAQ:ALPN) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
57.80%

Number Of
Insiders Buying
(Last 12 Months)
3

Amount Of
Insider Buying
(Last 12 Months)
$24.10 M

Number Of
Insiders Selling
(Last 12 Months)
2

Amount Of
Insider Selling
(Last 12 Months)
$10.28 M

Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Get ALPN Insider Trade Alerts

Want to know when executives and insiders are buying or selling Alpine Immune Sciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.


Alpine Immune Sciences (NASDAQ ALPN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2021Robert E ConwayDirectorBuy10,000$9.80$98,000.00  
9/17/2021Decheng Capital China Life SciMajor ShareholderBuy1,542,553$9.40$14,499,998.20  
9/17/2021Mitchell GoldCEOSell45,262$10.01$453,072.62  
9/17/2021Orbimed Advisors LlcDirectorBuy1,010,637$9.40$9,499,987.80  
9/15/2021Mitchell GoldCEOSell3,484$10.00$34,840.00  
6/28/2021Mitchell GoldCEOSell3,479$10.00$34,790.00168,380  
6/25/2021Mitchell GoldCEOSell9,473$10.01$94,824.73168,380  
5/19/2021Mitchell GoldCEOSell50,965$15.03$766,003.95179,074  
5/12/2021Mitchell GoldCEOSell10,000$11.68$116,800.00240,039  
4/13/2021Mitchell GoldCEOSell10,000$10.07$100,700.00260,039  
3/4/2021Mitchell GoldCEOSell10,000$13.01$130,100.00280,039  
12/28/2020Orbimed Advisors LlcDirectorSell600,000$14.25$8,550,000.00  
11/19/2020Robert E. ConwayDirectorBuy10,000$8.03$80,300.00  
5/30/2019James Paul RickeyVPBuy10,000$4.95$49,500.00  
2/8/2019Tiger Management L.L.C.Major ShareholderSell25,000$5.85$146,250.00  
1/18/2019James N TopperDirectorBuy372,439$5.37$1,999,997.43  
1/18/2019Mitchell GoldInsiderBuy190,875$5.37$1,024,998.75  
6/20/2017Value Fund L P BiotechnologyInsiderBuy17,806$2.25$40,063.50  
6/7/2017Bvf Partners L P/IlMajor ShareholderBuy36,900$2.28$84,132.00  
6/7/2017Value Fund L P BiotechnologyInsiderBuy72,650$2.29$166,368.50  
6/5/2017Bvf Partners L P/IlMajor ShareholderBuy35,750$2.29$81,867.50  
5/31/2017Value Fund L P BiotechnologyInsiderBuy47,000$2.27$106,690.00  
5/19/2017Value Fund L P BiotechnologyInsiderBuy78,858$2.30$181,373.40  
5/11/2017Value Fund L P BiotechnologyInsiderBuy109,034$2.32$252,958.88  
5/9/2017Robert E ConwayDirectorBuy5,000$2.34$11,700.0045,000  
5/8/2017Robert E ConwayDirectorBuy15,000$2.28$34,200.0060,000  
5/5/2017Janice TrohaEVPBuy10,000$2.34$23,400.0010,000  
5/5/2017Robert E ConwayDirectorBuy20,000$2.30$46,000.0040,000  
5/4/2017Robert E ConwayDirectorBuy10,000$2.26$22,600.0020,000  
1/4/2017David Malcom RodmanEVPSell6,687$2.27$15,179.4918,055  
12/2/2016R Michael CarruthersEVPBuy24,000$2.09$50,160.0024,000  
10/4/2016David Malcom RodmanEVPSell5,820$7.96$46,327.2018,056  
7/5/2016David Malcom RodmanCMOSell5,950$4.66$27,727.0018,055  
6/16/2016Jon CongletonCEOBuy5,000$3.87$19,350.0020,000  
3/24/2016Jon CongletonCEOBuy5,000$4.22$21,100.0015,000  
3/22/2016Jon CongletonCEOBuy5,000$4.38$21,900.0010,000  
12/11/2015Jon CongletonCEOBuy5,000$8.10$40,500.005,000  
12/9/2015Robert E ConwayDirectorBuy10,000$8.10$81,000.0010,000  
6/23/2015James E FlynnInsiderBuy250,000$14.00$3,500,000.00  
6/22/2015Bay Master Investors (C HawkesMajor ShareholderBuy17,200$14.69$252,668.00  
6/18/2015Bay Master Investors (C HawkesMajor ShareholderBuy20,400$14.47$295,188.00  
6/17/2015Global Healthcare Mas JennisonMajor ShareholderBuy26,149$14.00$366,086.00  
(Data available from 1/1/2013 forward)












Alpine Immune Sciences (NASDAQ:ALPN) Insider Trade Frequently Asked Questions

Who is on Alpine Immune Sciences's Insider Roster?

The list of insiders at Alpine Immune Sciences includes Decheng Capital China Life Sci, James N Topper, James Paul Rickey, Mitchell Gold, Orbimed Advisors Llc, Robert E Conway, and Tiger Management L.L.C..Learn more on ALPN's insiders

What percentage of Alpine Immune Sciences stock is owned by insiders?

57.80% of Alpine Immune Sciences stock is owned by insiders. Learn more on ALPN's insider holdings

Which Alpine Immune Sciences insiders have been buying company stock?

The following insiders have purchased Alpine Immune Sciences stock in the last 24 months: Decheng Capital China Life Sci ($14,499,998.20), Orbimed Advisors Llc ($9,499,987.80), and Robert E Conway ($98,000.00).

How much insider buying is happening at Alpine Immune Sciences?

Insiders have purchased a total of 2,573,190 Alpine Immune Sciences shares in the last 24 months for a total of $24,178,286.00 bought.

Which Alpine Immune Sciences insiders have been selling company stock?

The following insiders have sold Alpine Immune Sciences stock in the last 24 months: Mitchell Gold ($1,731,131.30), and Orbimed Advisors Llc ($8,550,000.00).

How much insider selling is happening at Alpine Immune Sciences?

Insiders have sold a total of 742,663 Alpine Immune Sciences shares in the last 24 months for a total of $10,281,131.30 sold.

This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.